A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT-Reference-Cited by-同舟云学术

A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT

Published:2019-05-03 Issue:1 Volume:9 Page:
ISSN:2191-219X
Container-title:EJNMMI Research
language:en
Short-container-title:EJNMMI Res

Author:

Gormsen Lars C.^ORCID,Vendelbo Mikkel H.,Pedersen Mette Abildgaard,Haraldsen Ate,Hjorthaug Karin,Bogsrud Trond Velde,Petersen Lars J.,Jensen Karen Juul,Brøndum Rasmus,El-Galaly Tarec C.

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1186/s13550-019-0503-z.pdf

Reference32 articles.

1. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80. https://doi.org/10.1200/JCO.2009.26.2493 .

2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90. https://doi.org/10.1200/JCO.2010.28.1618 .

3. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. https://doi.org/10.1182/blood-2017-03-769620 .

4. Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34:4015–22. https://doi.org/10.1200/JCO.2016.67.2980 .

5. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076–88. https://doi.org/10.1016/S1470-2045(17)30444-8 .

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma;European Radiology;2023-10-09

2. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime;Nature Reviews Clinical Oncology;2023-07-17

3. Inclusion of Metabolic Tumor Volume in Prognostic Models of Bone and Soft Tissue Sarcoma Increases the Prognostic Value;Cancers;2023-01-28

4. Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation;Computational and Structural Biotechnology Journal;2023

5. Relationship between ¹⁸F-FDG PET/CT Semi-Quantitative Parameters and International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society Classification in Lung Adenocarcinomas;Korean Journal of Radiology;2022